Sildenafil in COVID-19

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 19, 2020

Primary Completion Date

April 30, 2021

Study Completion Date

June 30, 2021

Conditions
Covid19SARS-COV2 Infection
Interventions
DRUG

Sildenafil

Patients allocated to this arm will receive Sildenafil 25mg every 8 hours orally for up to seven consecutive days.

DRUG

Placebo

Patients allocated to this arm will receive a matching placebo similar to Sildenafil pills used in the intervention arm. Placebos will be delivered orally every 8 hours for up to seven consecutive days.

Trial Locations (1)

Unknown

Hospital Naval Almirante Nef, Viña del Mar

All Listed Sponsors
collaborator

Hospital Naval Almirante Nef, Viña del Mar, Chile

UNKNOWN

lead

Universidad Nacional Andres Bello

OTHER

NCT04489446 - Sildenafil in COVID-19 | Biotech Hunter | Biotech Hunter